- Home
- SCYX vs NTIP Comparison
SCYX vs NTIP Comparison
Compare SCYX & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- NTIP
- Stock Information
- Founded
- SCYX 1999
- NTIP 1990
- Country
- SCYX United States
- NTIP United States
- Employees
- SCYX N/A
- NTIP N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- SCYX Health Care
- NTIP Miscellaneous
- Exchange
- SCYX Nasdaq
- NTIP Nasdaq
- Market Cap
- SCYX 28.5M
- NTIP 28.6M
- IPO Year
- SCYX 2014
- NTIP 1998
- Fundamental
- Price
- SCYX $0.82
- NTIP $1.37
- Analyst Decision
- SCYX
- NTIP
- Analyst Count
- SCYX 0
- NTIP 0
- Target Price
- SCYX N/A
- NTIP N/A
- AVG Volume (30 Days)
- SCYX 176.2K
- NTIP 26.2K
- Earning Date
- SCYX 08-07-2025
- NTIP 08-11-2025
- Dividend Yield
- SCYX N/A
- NTIP 7.49%
- EPS Growth
- SCYX N/A
- NTIP N/A
- EPS
- SCYX N/A
- NTIP N/A
- Revenue
- SCYX $2,630,000.00
- NTIP $250,000.00
- Revenue This Year
- SCYX $463.61
- NTIP N/A
- Revenue Next Year
- SCYX $310.80
- NTIP N/A
- P/E Ratio
- SCYX N/A
- NTIP N/A
- Revenue Growth
- SCYX N/A
- NTIP N/A
- 52 Week Low
- SCYX $0.66
- NTIP $1.16
- 52 Week High
- SCYX $2.29
- NTIP $1.78
- Technical
- Relative Strength Index (RSI)
- SCYX 57.87
- NTIP 62.14
- Support Level
- SCYX $0.67
- NTIP $1.20
- Resistance Level
- SCYX $0.75
- NTIP $1.30
- Average True Range (ATR)
- SCYX 0.04
- NTIP 0.06
- MACD
- SCYX 0.01
- NTIP 0.01
- Stochastic Oscillator
- SCYX 93.53
- NTIP 69.23
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.